The authoritative source for research information and outputs is Elsevier Scopus, with researcher profile verification from the Deanship of Scientific Research.
المخرجات
Research outputs
Articles, reviews, conference papers and book chapters, indexed by DOI and linked to University researchers.
(turmeric), and have received much attention due to their pleiotropic anticancer properties. Recent evidence suggests that curcumin and analogs prevent the activation of a variety of signaling pathways, including the MAPK, PI3K/Akt, and NF-kB pathways, resulting in the induction of apoptosis, prevention of proliferation, and suppression. In addition to these processes, curcumin has been shown to enhance the efficacy of the conventional anti-cancer modalities such as radiation and chemotherapy. By suppressing the expression of matrix metalloproteinases (MMPs), which are enzymes that break down the extracellular matrix and promote cancer cell invasion and metastasis, curcumin also demonstrates anti-metastatic qualities. Inflammation and the advancement of cancer are linked to the NF-κB signaling pathways, which are also suppressed by curcuminoids. Along with these processes, curcumin has demonstrated the ability to improve the effectiveness of traditional cancer treatments, including radiation and chemotherapy. It increases the sensitivity of cancer cells to various therapies, which enhances the therapeutic results. However, curcumin's low bioavailability limits its therapeutic use. Its anticancer potency may be increased, and this restriction may be overcome due to recent developments in drug delivery technologies, such as curcumin-loaded nanoparticles. Since they can target several different molecular pathways and improve the effectiveness of current treatments, curcuminoids are a promising family of chemicals for the prevention and treatment of cancer.
International Journal of Analytical Chemistry · vol. 2026 (1) · 4376722-4376722
Dasatinib, a therapy for chronic myeloid leukemia, suffers from poor bioavailability. Self‐microemulsifying drug delivery systems (SMEDDSs) are used to improve its dissolution. This study aimed to develop and validate a novel reverse‐phase high‐performance liquid chromatography (RP‐HPLC) method for quantifying dasatinib in SMEDDS formulations. The RP‐HPLC method utilized a mobile phase of methanol and 0.1% trifluoroacetic acid (55:45, v/v) and identified a peak wavelength for dasatinib at 324 nm. SMEDDS formulations comprised Capryol 90, Transcutol HP, and Tween 40. The method was validated according to ICH guidelines, demonstrating excellent linearity ( R 2 = 0.9993), accuracy (recovery between 98% and 101%), and precision (relative standard deviation of 0.73%). It also showed stability and reliability with limits of detection and quantification of 0.17 and 0.50 µg/mL, respectively. This RP‐HPLC method meets all validation criteria and provides a robust, cost‐effective tool for analyzing dasatinib in SMEDDS formulations.
dasatinibself-microemulsifying drug delivery systemRP-HPLC method developmentmethod validation
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed as antidiabetic agents, have emerged as candidate disease-modifying therapies for Parkinson’s disease (PD) and Alzheimer’s disease (AD), reflecting the widespread expression of GLP-1 receptors across neurons, glia, and the cerebral vasculature. This narrative review synthesizes mechanistic, clinical trial, and biomarker evidence for GLP-1 RAs in PD and AD, based on a literature search of PubMed, Embase, Scopus, and Web of Science, with ClinicalTrials.gov searched separately for trial protocols and results, through May 2026. Preclinical data implicate GLP-1 receptor agonism in anti-neuroinflammatory signaling, mitochondrial preservation, autophagy and proteostasis enhancement, anti-apoptotic effects, synaptic plasticity, cerebrovascular protection, and glymphatic clearance. Clinical evidence in PD is mixed and agent- and formulation-dependent: the phase II Exenatide-PD trial reported a motor benefit that persisted after washout (∼3.5-point between-group difference in MDS-UPDRS Part III), and the phase II LIXIPARK trial (lixisenatide) reported a significant 3.08-point between-group difference (95% CI 0.86–5.30; p = 0.007) favoring lixisenatide, whereas the larger, longer phase III Exenatide-PD3 trial, using an extended-release weekly formulation, found no significant effect on the same endpoint (adjusted coefficient 0.92; 95% CI −1.56 to 3.39; p = 0.47); oral semaglutide is under investigation in the ongoing phase II MOST-ABLE trial. In AD, the phase IIb liraglutide (ELAD) trial did not achieve statistical benefit on either its primary imaging endpoint (cerebral glucose metabolic rate; p = 0.14) or on most secondary cognitive measures, and the phase III semaglutide trials EVOKE and EVOKE+ did not meet their primary CDR-SB endpoint (estimated difference −0.08, 95% CI −0.35 to 0.20, p = 0.57 in EVOKE; 0.10, 95% CI −0.17 to 0.38, p = 0.46 in EVOKE+), despite biomarker signals including reductions in cerebrospinal fluid tau species and inflammatory markers. Comparative pharmacology reveals substantial heterogeneity in central nervous system penetration, receptor engagement, and systemic bioavailability across exenatide, liraglutide, semaglutide, and the imbalanced GLP-1/GIP co-agonist tirzepatide, complicating cross-agent extrapolation. Persistent challenges include separating direct neuroprotection from indirect metabolic and cardiovascular benefit, limited characterization of brain drug exposure, trial durations that may be short relative to the expected latency of a disease-modifying effect, and the absence of validated response biomarkers. We conclude that although the mechanistic and epidemiological rationale for GLP-1 RAs in neurodegeneration remains biologically plausible, current trial evidence does not yet support their use outside clinical trials, irrespective of comorbid diabetes status; future studies should prioritize earlier intervention, biomarker-guided patient selection, adequately powered subgroup analyses, and brain-penetrant formulations.
International Journal of Molecular Sciences · vol. 27 (20) · 9280-9280
There is growing interest in natural bioactive compounds as potentially safer and more sustainable sources of therapeutic agents. Terpenoids, one of the most structurally diverse and biologically active classes of natural products, are derived from repeating isoprene units and possess a broad range of pharmacological and industrial applications. This review provides a comprehensive overview of recent advances in terpenoid biosynthesis, structural classification, and therapeutic applications. It also discusses emerging approaches for enhancing large-scale production, improving functional efficacy, and overcoming pharmacokinetic limitations. Attention is given to terpenoids currently undergoing clinical evaluation, along with their progress toward commercial development. Despite substantial preclinical evidence supporting their therapeutic potential, the clinical translation of many terpenoids remains limited. Key challenges include poor aqueous solubility, low permeability, slow dissolution, and high lipophilicity, which can collectively restrict systemic bioavailability and therapeutic efficacy. Moreover, only a relatively small proportion of biologically active terpenoids have progressed to advanced stages of clinical development, highlighting a considerable gap between experimental findings and clinical application. This review integrates current knowledge of terpenoid biosynthesis, biological activities, production strategies, and translational development while highlighting sustainable and scientifically driven approaches that may facilitate their future therapeutic and commercial utilization.
International Journal of Clinical and Medical Research · vol. 3 (1) · 34-39
Arthritis represents a heterogeneous group of inflammatory and degenerative joint disorders characterized by persistent inflammation, oxidative stress, cartilage degradation, synovial dysfunction and progressive impairment of joint integrity. Rheumatoid Arthritis (RA) and Osteoarthritis (OA), although distinct in etiology, share several pathological mechanisms involving excessive production of Reactive Oxygen Species (ROS), mitochondrial dysfunction, inflammatory cytokine activation and dysregulation of redox-sensitive signaling pathways [1-4]. The nuclear factor erythroid 2-related factor 2 (Nrf2)-Kelch-like ECH-associated protein 1 (Keap1) pathway is a major endogenous defense mechanism responsible for maintaining cellular redox homeostasis. Under basal conditions, Keap1 promotes Nrf2 degradation; however, oxidative or electrophilic stress disrupts this interaction, allowing Nrf2 to accumulate and translocate into the nucleus, where it activates antioxidant response element (ARE)-dependent genes, including heme oxygenase-1 (HO-1), NAD(P)H quinone dehydrogenase 1 (NQO1) and glutathione-related enzymes [5,6]. Increasing evidence indicates that impaired or insufficient Nrf2 activity contributes to persistent oxidative stress and inflammation in arthritic joints [1,7]. Nrf2 also interacts with major inflammatory pathways, particularly nuclear factor-kappa B (NF-κB), mitogen-activated protein kinase (MAPK) and NLRP3 inflammasome signaling [8]. Nanotechnology offers an opportunity to improve the delivery, stability, bioavailability and tissue targeting of therapeutic agents capable of modulating redox and inflammatory pathways. Among different nanomaterials, silver nanoparticles (AgNPs) have attracted considerable interest because of their antimicrobial, anti-inflammatory, antioxidant and immunomodulatory properties [9-11]. Experimental studies have demonstrated that AgNPs can reduce inflammatory cytokines, regulate NF-κB and MAPK signaling, influence macrophage polarization and alleviate inflammatory tissue injury [9,10]. In experimental RA, targeted folic-acid-modified AgNPs have demonstrated the ability to interact with inflammatory macrophages, promote macrophage apoptosis and repolarization and reduce disease severity [12]. Nevertheless, the relationship between AgNP exposure, oxidative signaling and Nrf2-Keap1 activation is complex and excessive nanoparticle-induced oxidative stress may also produce adverse biological effects. This review examines the role of the Nrf2-Keap1 pathway in arthritis, evaluates nanoparticle-based strategies for modulating redox and inflammatory mechanisms and critically discusses the therapeutic potential and safety considerations of AgNPs. Particular emphasis is placed on the potential intersection between AgNP-mediated redox regulation, Nrf2-Keap1 signaling, NF-κB inhibition, macrophage polarization and joint protection.
Pea protein is gaining global attention as a sustainable, plant-based alternative to animal proteins due to its lower environmental impact. However, conventional thermal processing methods can degrade its functional and nutritional properties. This review explores sustainable non-thermal approaches for pea protein processing, focusing on pre-treatment, extraction, and modification. Ultrasonication is the most effective extraction technique and offers higher protein content (82.76 to 85.76%) compared to alkaline, air classification, and enzymatic methods. For protein modification, enzymatic treatment proves most effective, enhancing digestibility by 20.86 to 22.50% and solubility by 64.28 to 66.55%, while preserving structural integrity, compared to other non-thermal techniques. We critically assess the impact of these techniques on protein conformation, allergenicity reduction, and bioavailability and discuss their applications in food formulations and plant-based alternatives. Despite technological advances, significant research gaps remain in understanding molecular structural changes and challenges in industrial scalability. Future studies should focus on scaling processing methods.
pea proteinnon-thermal processingsonicationprotein extraction
The revolution in the 21st century has witnessed the development of the industrial and healthcare systems. Human health and well-being are still global challenges despite this modernization and advancement. Cancer is extensively affecting people, demanding special attention and an effective dietary approach. Bioactive compound-based natural therapies are a significant strategy to reduce the cancer burden. Naringenin, a bioactive compound widely distributed in the citrus family and is known for several health-promoting properties, including anticancer activity. The current review highlights the anticancer potential of Naringenin by exploring recent studies through various databases like Google Scholar, PubMed, ScienceDirect, and Web of Science. The analyses revealed that Naringenin can inhibit cell proliferation and oncogenesis through different molecular mechanisms and signaling pathways like apoptosis induction, cell cycle arrest, and modulation of P13K/AKT/mTOR, TGF-β1/Smad3, NF-κB, TLR4, and MAPK pathways. Moreover, it can inhibit inflammatory markers (IL-6, TNF-α, and IL-1β), downregulate oncogenes (Ras, HER2, MYC, and BCR/ABL1), and upregulate tumor suppressor genes (TSGs) such as TP53, PTEN, and BRCA1 and BRCA2 expression. Combining Naringenin with other bioactive compounds, chemotherapy drugs, and nanoformulations is a novel way to enhance its anticancer activity. However, poor bioavailability, stability, and lack of clinical trials and in silico studies hinder its therapeutic potential. Therefore, advanced techniques to enhance its stability and clinical trials regarding anticancer potential are required to validate its promising efficacy. The current review focuses on Naringenin's bioavailability, antioxidant, and anticancer potential through possible mechanisms.
Georgi. It has been recognized as an active phytochemical with specific therapeutic potential and significant pharmacological effects, especially in cancer research. Nevertheless, increasing preclinical data both in vitro and in vivo demonstrate its effectiveness against a broad spectrum of cancers, including breast, ovarian, lung, gastric, colorectal, prostate, renal, glioblastoma, and hematological types. Wogonin exerts its anticancer effects through a complex mechanism that involves the induction of programmed cell death (apoptosis), autophagic modulation, and cell cycle arrest. It also suppresses angiogenesis of tumors, epithelial-mesenchymal transition (EMT), invasion, metastasis, and multidrug resistance effects. The effects are supported by the compound's ability to regulate a variety of oncogenic and tumor-suppressive signaling pathways, particularly PI3K/Akt, STAT3, NF-kB, MAPK, AMPK, and Wnt/beta-catenin. It modulates apoptosis-related proteins (Bax, Bcl-2, PARP, caspases) and transcription factors. Wogonin has been shown to enhance the antitumor effects of established chemotherapeutic agents, and it works synergistically with these drugs in multiple cancer models, with the added benefits of reduced systemic toxicity. Nevertheless, it has poor oral bioavailability and water solubility, which limits its clinical application. Recent advances in nanocarriers and liposomal delivery systems show promise in overcoming pharmacokinetic challenges. This review consolidates available pharmacological, mechanistic, and pharmacokinetic evidence of wogonin, highlights its potential in combination therapies, and identifies research gaps and formulation strategies necessary for advancing this candidate towards clinical development as a novel anticancer agent.
Environmental Pollutants and Bioavailability · vol. 37 (1)
This study assessed the effect of thiamethoxam on the Nile tilapia (Oreochromis niloticus) under subacute and chronic exposure. The study focused on biochemical markers, genetic damage, pesticide residue levels in fish flesh, and histopathological changes in fish exposed to different concentrations of thiamethoxam (25, 50) for 30 days and (100, 250 mg/L) for 4 days. The study found that prolonged exposure to high doses of thiamethoxam (50 mg/L for 30 days) had significant negative effects on fish health. This exposure led to increased levels of urea and ALT in the blood, indicating potential damage to the kidneys and liver. Additionally, thiamethoxam caused oxidative stress, as evidenced by elevated levels of MDA and upregulated TLR2 gene expression. Thiamethoxam also negatively impacted the fish’s antioxidant defense system. It significantly reduced the expression of key antioxidant genes like ghrelin and catalase, particularly at 250 mg/L for 4 days. The total antioxidant capacity (TAC) and superoxide dismutase (SOD) levels remained relatively stable, except for slight decreases at the highest dose. Thiamethoxam residues were detected in the muscle tissue of fish, with the highest levels found in the 250 mg/L for 4 days. Histological examination revealed severe degenerative changes in the gills and liver tissues of the fish exposed to thiamethoxam, with the severity of the damage increasing with the concentration of the pesticide. In conclusion, cautions must be taken when we use neonicotinoids due to its negative feedback impact on Nile Tilapia fish health and consequently affect humans as a final consumer.
Background Theobromine derivatives have emerged as promising anticancer agents, but their therapeutic potential is limited by poor bioavailability. This study investigates a chitosome-based delivery system for a novel theobromine derivative, N -(4-Chlorophenyl)-2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1 H -purin-1-yl)acetamide ( T-1-PCPA ), to evaluate its anticancer potential. Methods T-1-PCPA -loaded chitosomess ( T-1-PCPA loaded chitosomes) were formulated using the thin film hydration technique. Molecular docking was employed to computationally assess the stability of the T-1-PCPA loaded chitosomes. Experimentally, various physicochemical properties, including particle size, polydispersity index (PDI), zeta potential, and entrapment efficiency, were analyzed. Transmission electron microscopy (TEM) was used to investigate morphological features. In vitro , the cytotoxicity of the T-1-PCPA -PC-CS was evaluated on HCT-116 and A549 cancer cell lines. Further mechanistic studies included cell cycle analysis, apoptosis detection, and cell migration assays were performed. Results The T-1-PCPA loaded chitosomes exhibited good colloidal stability, with well-defined spherical particles averaging 142.6 ± 4.3 nm in size, a zeta potential of +32.4 ± 1.6 mV, and an entrapment efficiency of 89.2 ± 2.1%, indicating efficient drug loading and formulation stability. In vitro cytotoxicity assays revealed significantly enhanced anticancer activity, with IC 50 values of 8.05 ± 0.06 μg/mL for HCT-116 and 9.55 ± 0.15 μg/mL for A549 cells—substantially lower than those of free T-1-PCPA and blank formulations. Flow cytometric cell cycle analysis demonstrated arrest at G0-G1 and S phases, while apoptosis analysis revealed a significant increase in total apoptosis (39.55%) in treated HCT-116 cells. Cell migration assays showed a 63.4% reduction in migration compared to control, supporting the formulation's anti-migratory potential. Conclusion T-1-PCPA -loaded chitosomes system shows strong potential as a targeted anticancer nanotherapy, demonstrating enhanced cytotoxicity, apoptosis induction, cell cycle arrest, and anti-migratory activity. With high drug loading, stability, and selectivity toward cancer cells, it addresses key limitations of conventional chemotherapy. These findings warrant further preclinical evaluation for colorectal and lung cancer treatment.
chitosomestheobromine derivativesanticancer drug deliverydrug encapsulation
Toxicology Research · vol. 14 (3) · tfaf034-tfaf034
Abstract Peptic ulcer is a chronic inflammatory disorder affecting large portion of population with difficulty in treatment. Treatment options include inhibition of gastric acid secretion, histamine inhibitors, eradication of Helicobacter pylori infection and tissue lining protection. These therapeutic options have several side effects, low bioavailability and bio-distribution. To further increase bioavailability, control release, stability, site specific delivery and minimize organoleptic side effects of phytochemical, nano-encapsulation is a suitable strategy. Chitosan is a suitable nano-carrier for drug delivery applications in treating peptic ulcer as it is biodegradable, biocompatible, safe and cost-effective. Therefore, Ficus religiosa (FR) leaf extract was loaded into chitosan NPs by ion gelation method for in vivo anti-ulcerative activity in indomethacin-induced peptic ulcer rats. Results showed that FR extract was successfully loaded into CNPs with 84% encapsulation efficiency while the size of empty CNPs was reported to be 620.3 nm as compared to FR-loaded CNPs 811.5 nm. FR-loaded CNPs showed homogeneous size distribution as well greater physical stability. Furthermore, in vivo studies revealed gastro-protective activity of FR-loaded CNPs in reducing the ulcer index (UI) to 0.51 (71.30% inhibition) while indomethacin only untreated rats showed UI 2.99 and insignificant ulcer inhibition 11.02%. Furthermore, FR-loaded CNPs restored gastric pH, healed rat stomach completely without ulcers or hemorrhagic spot and improved antioxidants and blood profiles compared to plant extract or CNPs. These findings confirmed the effective application of FR extract loaded CNPs as anti-ulcer agents and reinforces the importance of nano-encapsulation in improving drug efficacy.
Lung inflammation is a hallmark of several respiratory diseases. Despite the great effectiveness of the synthetic antiinflammatory agents, they cause potential side effects. Polydatin (PD), a natural phytomedicine, has antioxidant and antiinflammatory effects. Its clinical applications are hindered due to poor aqueous solubility, low bioavailability, and rapid metabolism by first-pass effect. Herein, we report the development of a novel chitosan oligosaccharide-coated PD-loaded Poly dl-lactide-co-glycolide nanoparticles (COS-coated PD/PLGA NPs) against a bleomycin-induced pulmonary inflammation in a rat model. The NPs exhibited a small particle size of 188.57 ± 5.68 nm and a high zeta potential of + 18.13 ± 2.75 mV with spherical architecture and sustained release pattern of PD. In vivo studies in bleomycin-induced lung inflammation in a rat model revealed the superior prophylactic activity of COS-coated PD/PLGA NPs over the free drug (PD) as demonstrated by histopathological and immunohistochemical analyses, alongside biochemical assays evaluating oxidative stress biomarkers and inflammatory cytokine levels. Overall, the optimized COS-coated PD/PLGA NPs formulation offers a promising prophylactic platform against many respiratory diseases.
Gallic acid (GA) is a well-known herbal bioactive compound found in many herbs and foods like tea, wine, cashew nuts, hazelnuts, walnuts, plums, grapes, mangoes, blackberries, blueberries, and strawberries. GA has been reported for several pharmacological activities, such as antioxidant, inflammatory, antineoplastic, antimicrobial, etc. Apart from its incredible therapeutic benefits, it has been associated with low permeability and bioavailability issues, limiting their efficacy. GA belongs to BCS (Biopharmaceutics classification system) class III (high solubility and low probability). In this context, novel drug delivery approaches played a vital role in resolving these GA issues. Nanocarrier systems help improve drug moiety's physical and chemical stability by encapsulating them into a lipidic or polymeric matrix or core system. In this regard, researchers have developed a wide range of nanocarrier systems for GA, including liposomes, transfersomes, niosomes, dendrimers, phytosomes, micelles, nanoemulsions, metallic nanoparticles, solid lipid nanoparticles (SLNs), nanoparticles, nanostructured lipid carriers, polymer conjugates, etc. In the present review, different search engines like Scopus, PubMed, ScienceDirect, and Google Scholar have been referred to for acquiring recent information on the theme of the work. Therefore, this review paper aims to emphasize several novel drug delivery systems, patents, and clinical updates of GA.
Beilstein Journal of Nanotechnology · vol. 15 · 1473-1497
Phytochemicals, naturally occurring compounds in plants, possess a wide range of therapeutic properties, including antioxidant, anti-inflammatory, anticancer, and antimicrobial activities. However, their clinical application is often hindered by poor water solubility, low bioavailability, rapid metabolism, and instability under physiological conditions. Polymer lipid hybrid nanoparticles (PLHNPs) have emerged as a novel delivery system that combines the advantages of both polymeric and lipid-based nanoparticles to overcome these challenges. This review explores the potential of PLHNPs to enhance the delivery and efficacy of phytochemicals for biomedical applications. We discuss the obstacles in the conventional delivery of phytochemicals, the fundamental architecture of PLHNPs, and the types of PLHNPs, highlighting their ability to improve encapsulation efficiency, stability, and controlled release of the encapsulated phytochemicals. In addition, the surface modification strategies to improve overall therapeutic efficacy by site-specific delivery of encapsulated phytochemicals are also discussed. Furthermore, we extensively discuss the preclinical studies on phytochemical encapsulated PLHNPs for the management of different diseases. Additionally, we explore the challenges ahead and prospects of PLHNPs regarding their widespread use in clinical settings. Overall, PLHNPs hold strong potential for the effective delivery of phytochemicals for biomedical applications. As per the findings from pre-clinical studies, this may offer a promising strategy for managing various diseases.
Colloids and Interface Science Communications · vol. 64 · 100814-100814
Lipid nanoparticles (LNPs) represent a groundbreaking advancement in the realms of cosmetics and dermatology, providing advantages over traditional formulations. This paper explores the revolutionary potential of LNPs, particularly Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs), in enhancing cosmetic and dermatological applications. The review highlights the advantages of LNPs, including improved skin penetration, improved bioavailability and controlled release of active ingredients, which together contribute to their superior performance compared to conventional formulations. Notable applications discussed include their roles in acne treatment, anti-aging solutions, wound healing , skin-lightening products, and sunscreens . This study examines the structural features and formulation techniques of LNPs, highlighting biocompatibility , and targeted delivery capabilities. We also explore emerging uses such as genetic medicine and mRNA vaccine delivery, alongside market trends and consumer acceptance. By summarizing recent developments and identifying existing challenges, this paper offers a thorough overview of LNPs for future research in pharmaceutical and cosmetic advancements.